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Francisco Averhoff, Peter Vickerman
Summary
Background The WHO elimination strategy for hepatitis C virus advocates scaling up screening and treatment to 
reduce global hepatitis C incidence by 80% by 2030, but little is known about how this reduction could be achieved 
and the costs of doing so. We aimed to evaluate the effects and cost of different strategies to scale up screening and 
treatment of hepatitis C in Pakistan and determine what is required to meet WHO elimination targets for incidence. 
Methods We adapted a previous model of hepatitis C virus transmission, treatment, and disease progression for 
Pakistan, calibrating using available data to incorporate a detailed cascade of care for hepatitis C with cost data on 
diagnostics and hepatitis C treatment. We modelled the effect on various outcomes and costs of alternative scenarios 
for scaling up screening and hepatitis C treatment in 2018–30. We calibrated the model to country-level demographic 
data for 1960–2015 (including population growth) and to hepatitis C seroprevalence data from a national survey in 
2007–08, surveys among people who inject drugs (PWID), and hepatitis C seroprevalence trends among blood donors. 
The cascade of care in our model begins with diagnosis of hepatitis C infection through antibody screening and RNA 
confirmation. Diagnosed individuals are then referred to care and started on treatment, which can result in a sustained 
virological response (effective cure). We report the median and 95% uncertainty interval (UI) from 1151 modelled runs.
Findings One-time screening of 90% of the 2018 population by 2030, with 80% referral to treatment, was projected to 
lead to 13·8 million (95% UI 13·4–14·1) individuals being screened and 350 000 (315 000–385 000) treatments started 
annually, decreasing hepatitis C incidence by 26·5% (22·5–30·7) over 2018–30. Prioritised screening of high 
prevalence groups (PWID and adults aged ≥30 years) and rescreening (annually for PWID, otherwise every 10 years) 
are likely to increase the number screened and treated by 46·8% and decrease incidence by 50·8% (95% UI 
46·1–55·0). Decreasing hepatitis C incidence by 80% is estimated to require a doubling of the primary screening rate, 
increasing referral to 90%, rescreening the general population every 5 years, and re-engaging those lost to follow-up 
every 5 years. This approach could cost US$8·1 billion, reducing to $3·9 billion with lowest costs for diagnostic tests 
and drugs, including health-care savings, and implementing a simplified treatment algorithm.
Interpretation Pakistan will need to invest about 9·0% of its yearly health expenditure to enable sufficient scale up in 
screening and treatment to achieve the WHO hepatitis C elimination target of an 80% reduction in incidence by 2030.
Funding UNITAID.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
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Introduction
After the development of highly effective direct-acting 
antiviral treatments for hepatitis C, WHO developed a 
Global Health Sector Strategy to eliminate hepatitis C as 
a public health threat, setting targets to reduce the 
incidence of new hepatitis C infections by 80% and 
hepatitis C-related mortality by 65% by 2030 (compared 
with 2015 levels).1 In low-income and middle-income 
countries (LMICs), which account for 50–80% of 
the global hepatitis C burden,2,3 diagnosis rates are 
low (13·9%), with 7·1% of people (569 million) starting 
treatment in 2015, most of which occurred in Egypt.3
Pakistan has the second largest hepatitis C burden 
worldwide, with an estimated 7·0 million infections 
in 2013.4,5 Treatment is often insufficient, leading to 
increasing hepatitis C-related morbidity.5,6 Pakistan’s 
hepatitis C epidemic is generalised, with most hepatitis C 
transmission being attributable to routine community 
and medical-related practices.7,8
Since 2005, national and provincial hepatitis control 
programmes have been treating hepatitis C-infected 
patients, with about 150 000–160 000 patients starting 
treatment annually by 2015.9 From 2016, direct-acting 
antiviral therapies became available in Pakistan, and 
both the public and private sectors have been starting 
programmes to scale up hepatitis C treatment.9 This 
scale up depends on identifying infected cases; however, 
it is unknown what levels of screening, linkage to care, 
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and resources are needed to scale up treatment 
sufficiently to reach the WHO hepatitis C elimination 
targets by 2030.
We aimed to model the effects and cost of different 
strategies to scale up screening and treatment of 
hepatitis C in Pakistan, to determine what is required 
to reach the WHO hepatitis C elimination targets for 
incidence.
Methods
Model overview
We adapted a previous model of hepatitis C 
transmission, treatment, and disease progression for 
Pakistan5 to incorporate a detailed cascade of care for 
hepatitis C (figure 1, appendix pp 3–4). Consistent with 
the previous model, our new model incorporates 
population growth, age structure, and sex; hepatitis C 
transmission in the general population and among 
people who inject drugs (PWID); and hepatitis 
C-associated disease progression.
Briefly, we divided the population into three age 
categories: young (0–19 years), young adult (20–29 years), 
and adult (≥30 years). Individuals enter the young 
category at a birth rate dependent on population growth 
and are initially deemed to be susceptible to hepatitis C. 
They transition through the age categories, with some 
young adults becoming PWID. Mortality is age-specific 
and sex-specific, with PWID experiencing heightened 
drug-related mortality.10 Susceptible individuals become 
hepatitis C-infected at a rate dependent on their sex, age, 
and hepatitis C prevalence in the population. PWID have 
additional infection risk. Most newly infected individuals 
become chronically infected and progress to compensated 
cirrhosis if left untreated, and eventually end-stage liver 
disease (ie, decompensated cirrhosis, and hepatocellular 
carcinoma). End-stage liver disease is associated with 
See Online for appendix
Research in context
Evidence before this study
We searched PubMed for articles published between database 
inception and Aug 31, 2019, using the search terms (“HCV” 
OR “hepatitis C virus” OR “hep C”) AND (“mathematical” OR 
“dynamic” OR “transmission”) AND (“model” OR “models” 
OR “modelling” OR “modeling”) AND (“case-finding” OR 
“screening” OR “treatment”) AND (“cost” OR “costs” OR 
“costing”). No language restrictions were used. Many 
hepatitis C modelling studies have focused on projecting the 
effect and economic implications of testing and treatment 
interventions in specific subgroups, including people who inject 
drugs (PWID), men who have sex with men, and prisoners. 
A previous dynamic modelling approach studied the impact 
and cost-effectiveness of intervention packages to reduce HIV 
and hepatitis C infections among PWID in eastern Europe and 
central Asia, but did not consider levels of interventions that 
would reach elimination. Other studies have been done in 
high-income countries or have used static models 
(eg, Markov models) and so could not consider levels of 
treatment needed to reduce incidence. Only three studies 
presented cost-effectiveness or budget analyses of hepatitis C 
screening and treatment interventions in the general 
population of low-income and middle-income countries 
(LMICs), namely, Egypt, South Africa, and Pakistan. However, 
none of these studies used a dynamic modelling approach, nor 
did they consider the budgetary requirements for reducing 
country-level hepatitis C incidence to WHO-advocated 
elimination targets. The Pakistan analysis did not use locally 
collected cost data, which resulted in optimistic cost projections 
that are less representative of the Pakistan context.
Added value of this study
To our knowledge, this study is the first country-level estimation 
of the hepatitis C screening and treatment requirements, and 
associated costs, for achieving the WHO hepatitis C elimination 
incidence targets in a generalised epidemic LMIC setting, 
specifically Pakistan. The accuracy of our projections is 
maximised through calibrating a detailed model to context-
specific data from Pakistan, and in using real-world costs of 
screening and treatment for Pakistan. Our results provide 
valuable and practical new information on how each stage of 
the cascade of care for hepatitis C needs to be improved to 
achieve the WHO hepatitis C elimination target for incidence in 
Pakistan, and the costs of doing so. The implementation of 
effective hepatitis C screening strategies is also important, with 
our findings suggesting that prioritised screening of population 
subgroups with high prevalence of hepatitis C, such as adults 
and PWID, can improve the efficiency and effect of screening. 
These considerations will probably have a substantial effect on 
optimising the costs of achieving the WHO hepatitis C 
elimination targets, which our projections suggest will still be 
high with the cheapest available drug regimens and diagnostics. 
Importantly, our projections also show that substantial savings 
can be achieved through simplifying the screening and 
treatment pathway, a consideration that is relevant not only to 
Pakistan, but also to other LMICs.
Implications of all the available evidence
This study directly addresses the feasibility of eliminating 
hepatitis C at a country level, a prerequisite to achieving global 
elimination as set out by WHO. To achieve this aim, high 
screening coverage of the whole population is crucial, while 
strengthening all elements of the care continuum to ensure a 
high proportion of individuals are effectively cured. To 
minimise costs, screening strategies should prioritise testing 
and retesting in those with transmission potential and focus on 
maintaining high referral rates to ensure that diagnosed 
individuals are adequately linked to care and started on 
treatment.
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increased mortality.11 Reinfection can occur after 
successful treatment or spontaneous clearance.12,13
The cascade of care in our model begins with diagnosis 
of hepatitis C infection through antibody screening and 
RNA confirmation. Diagnosed individuals are then 
referred to care and initiated on treatment, which can 
result in a sustained virological response (effective cure). 
We assume that, each year, a proportion of the population 
is screened for hepatitis C antibodies for the first time, 
with previously tested seronegative individuals having 
specified retesting rates that vary across subgroups. 
Individuals testing antibody-positive can receive RNA 
testing, whereupon they become diagnosed with active 
infection if they are RNA-positive. Any antibody-positive 
individuals who are not aware of their current infection 
status can also be rescreened via RNA testing. Depending 
on possible eligibility criteria or the prioritisation of certain 
subgroups, a proportion of newly diagnosed individuals 
are referred to treatment. If treated, patients either achieve 
sustained virological response or fail treatment, after 
which they can be retreated. Although loss to follow-up can 
occur along the cascade of care, re-engagement can result 
in such individuals re-entering the diagnosed category.
Baseline model parameterisation and calibration
The model was parameterised using demographic, 
behavioural, and hepatitis C epidemiological data from 
Pakistan (table 1, appendix pp 30–33). We calibrated the 
model to country-level demographic data for 1960–2015 
(including population growth14,15) and to hepatitis C 
seroprevalence data (by age group and overall) from a 
national survey7 in 2007–08 (4·8% overall), surveys 
among PWID16,17 (56–69%), and hepatitis C seroprevalence 
trends among blood donors. These previous data suggest 
hepatitis C seroprevalence increased by 0·39% (95% CI 
–0·17 to 0·94%) per decade for 1994–2014 (appendix p 14).
Data on hepatitis C disease progression and mortality 
came from the literature.4 Treatment before 2016 using 
interferon-based therapy (50–81% sustained virological 
response)18 was modelled using in-country data (table 1; 
appendix p 33); whereas direct-acting antiviral treatments 
(80–95% sustained virological response) were used 
post-2016.13,19 No data on screening exists for Pakistan, so 
we calibrated the mean screening rate (3·7% [95% UI 
2·6–5·9]) to give the observed 150 000–160 000 treatments 
undertaken each year,9 while assuming a treatment 
referral rate of 35–70% based on Pakistan data.20
Uncertainty distributions were associated with most 
parameters and calibration data (appendix pp 30–33); 
the only exceptions being some unknown parameters 
estimated during the model calibration. To calibrate 
the model, we randomly sampled these uncertainty 
distributions to produce 4000 paired sets of parameters 
and calibration data. For each set, the unknown model 
parameters were varied to fit the model to the sampled 
calibration data for chronic hepatitis C prevalence by 
age and for PWID using a non-linear least squares 
optimisation algorithm in MATLAB (version 2018b; 
MathWorks, Natick, MA, USA). Parameter sets that 
did not produce model estimates within the 95% CI of 
the overall chronic hepatitis C prevalence from the 
2007–08 national survey were discarded, which produced 
1151 model fits that were used for subsequent analyses. 
We report the results as the median and 95% uncertainty 
interval (UI) from these modelled runs. Further details 
are given in the appendix (pp 13–18).
Model analyses
We used the calibrated model to evaluate various screening 
and treatment intervention scenarios from 2018. We 
assessed how each scenario improved the cascade of care 
for hepatitis C, and the percentage reduction in hepatitis C 
incidence and mortality by 2030 compared with 2015. 
Scenarios were also compared with a counterfactual of no 
treatment from 2018 (S0) and a status-quo scenario of 
maintaining current levels of treatment (150 000–160 000 
treatments per year) until 2030 (SQ).
In each scenario, we assume that all individuals with 
an antibody-positive test are tested for hepatitis C RNA. 
Figure 1: Simplified schematic of our HCV screening and treatment model
Solid lines indicate epidemiological transitions. Dashed lines indicate antibody or RNA (re)screening. Broadly, the 
population is split into three categories: those who have never been screened (and eligible for primary antibody 
screening); those who have been previously screened as antibody-negative (and are eligible for rescreening); and 
those who have been previously screened as antibody-positive. Individuals with known antibody-positive status 
are divided into two subcategories to indicate whether they have ever been diagnosed or not. The full HCV 
screening model schematic, including demographic and behavioural compartments, disease progression stages, 
HCV transmission dynamics, and the screening and treatment intervention cascade of care can be found in the 
appendix (pp 3–4). HCV=hepatitis C virus. SVR=sustained virological response.
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We then assume different proportions of referral of 
diagnosed individuals to treatment (ie, the referral rate), 
with the remainder being lost to follow-up. All referred 
patients start treatment, with those who do not achieve 
a sustained virological response being retreated. For 
simplicity, we only incorporate one event of loss to 
follow-up between diagnosis and referral, and believe 
that this assumption captures the effect of other forms 
of loss to follow-up between diagnosis and treatment. 
Unpublished data from Pakistan suggest that there is 
relatively little loss to follow-up after treatment initiation 
(data not shown), which can be accounted for in our 
sustained virological response data in the intention-to-
treat population. We assumed a treatment duration of 
12 weeks unless post-cirrhotic (24 weeks). The 
intervention scenarios are described in the panel, with 
model para meters shown in table 2 and the 
appendix (pp 17–19).
Baseline value or fitted range Source
Demographic parameters
Mean population growth rate per year, median (95% UI)
Before 2000 2·76% (2·53–2·99)* Pakistan Economic Survey;14 UN Department of Economic and Social Affairs, Population Division15 
2000–15 1·92% (1·54–2·31)* Pakistan Economic Survey;14 UN Department of Economic and Social Affairs, Population Division15 
After 2015 1·72% (uniform 1·35–2·08) Pakistan Economic Survey;14 UN Department of Economic and Social Affairs, Population Division15
Proportion of young adults who start injecting drug use, median (95% UI)
Men 0·032 (0·026–0·039)* Calibrated to fit proportion of men aged 15–64 years who inject drugs: 0·7%17
Women 0·009 (0·0004–0·017)* Calibrated to fit proportion of women aged 15–64 years who inject drugs: 0·01%17
Mean mortality
Young 1/56 Based on a life expectancy at birth of 66 years in 2015, and adjusted in model calibration to give 
proportion in 2015: 44%15
Young adult 1/41 Based on a life expectancy at birth of 66 years in 2015, and adjusted in model calibration to give 
proportion in 2015: 19%15
Adult Men 0·023 (0·020–0·026); 
women: 0·020 (0·017–0·024)*
Based on a life expectancy at birth of 66 years in 2015, and adjusted in model calibration to give 
proportion in 2015: 37%15
Additional drug-related mortality, median (95% UI) 0·028 (log-normal 0·020–0·039) Based on estimates of drug-related mortality across Asia10
Transmission parameters
HCV transmission rate per susceptible person in each age group, median (95% UI)
Young (β1) 0·059 (0·052–0·066)* Fit to chronic prevalence in young people (aged 0–19 years) from 2007–08 Pakistan national 
survey7 on viral hepatitis: 1·5%
Young adult (β2) 0·053 (0·023–0·085)* Fit to chronic prevalence in young adults (aged 20–29 years) from 2007–08 Pakistan national 
survey7 on viral hepatitis: 3·2%
Adult (β3) 0·12 (0·10–0·14)* Fit to chronic prevalence in adults (aged ≥30 years) from 2007–08 Pakistan national survey7 on 
viral hepatitis: 6·9%
Additional HCV transmission rate for injecting 
drug use, median (95% UI)
0·61 (0·51–0·74)* Fit to chronic prevalence in PWID16 in 2012: 62·2% (55·5–68·8)
Proportion of infections that spontaneously clear 0·26 (uniform 0·22–0·29) Systematic review of spontaneous HCV clearance12
Treatment parameters
Treatment rate per capita before 2018†
2005–10 57 500 Pakistan Health Research Council (Mahmood H, PHRC, personal communication)
2011 137 970 Pakistan Health Research Council (Mahmood H, PHRC, personal communication)
2012 129 398 Pakistan Health Research Council (Mahmood H, PHRC, personal communication)
2013 137 910 Pakistan Health Research Council (Mahmood H, PHRC, personal communication)
2014 115 920 Pakistan Health Research Council (Mahmood H, PHRC, personal communication)
2015–17 152 710 Pakistan Health Research Council (Mahmood H, PHRC, personal communication)
Mean duration on treatment
Before 2016 24 weeks WHO HCV Treatment Guidelines13
2016 onward 12 weeks for pre-cirrhotic patients, 
24 weeks for post-cirrhotic patients
WHO HCV Treatment Guidelines13
SVR rate with interferon and ribavirin treatment 0·66 (uniform 0·50–0·81) Studies on SVR rates for conventional HCV treatment in Pakistan18
SVR rate with new direct-acting antiviral treatments 0·9 (uniform 0·80–0·95) WHO HCV Treatment Guidelines;13 review of direct-acting antivirals in Pakistan19
Data are baseline values (range) unless otherwise stated. Rates are per year. HCV=hepatitis C virus. PHRC=Pakistan Health Research Council. PWID=people who inject drugs. SVR=sustained virological response. 
UI=uncertainty interval. *Fitted data shown as median (95% UI). †Calibrated to historical treatment rates, total estimated historical HCV treatments before 2018 are given, assuming a public and private sector 
split of 40:60% (appendix p 33). Direct-acting antivirals were available from 2016 onwards.
Table 1: Main baseline model parameters with associated uncertainty ranges
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Estimation of screening and treatment costs
We estimated the total costs of each scenario to assess 
the affordability of widespread hepatitis C screening 
and treatment scale up. Cost data for undertaking 
hepatitis C testing and treatment (including materials, 
equipment, and staff time) came from a Médecins Sans 
Frontières hepatitis C treatment clinic in Machar 
Colony, Karachi from 2016 to 2017.21,22 A patient-level 
costing analysis was done using a provider’s perspective 
in 2018 US$ (appendix pp 16–17, 34–39). Treatment 
costs were adapted for generic sofosbuvir ($15 for 
28-day supply3) and daclatasvir ($21 for 28-day supply), 
giving a total treatment unit cost of $403 for a 12-week 
treatment course and $586 for 24 weeks, inclusive of 
drug, visit, and laboratory costs. All costs were valued at 
local rates. Screening unit costs were estimated to be 
$10–17 per antibody test and $34–41 per RNA test, 
including staff costs. Actual test kits were $2·15 for 
antibody testing and $24·09 for RNA testing. Health-
care costs for management of hepatitis C disease (other 
than curative treatment) were not included in the 
baseline cost estimates owing to a lack of data for 
Pakistan, but have been considered in the sensitivity 
analyses using adjusted costs from Cambodia (appendix 
Panel: Model scenarios
Scenario S0
No further treatment from 2018 onwards.
Scenario SQ
While assuming a range of referral rates (35–70%), the mean 
screening rate (3·7% [95% UI 2·6–5·9] of population per year) is 
calibrated to maintain current levels of treatment (ie, status quo).
Scenario S1
One-time random screening of 90% of the 2018 Pakistan 
population by end of 2030, equating to about 6·2% screened 
annually, with 80% of diagnosed individuals referred to 
treatment. This is the screening target set by WHO.1,3
Scenario S2
One-time screening (as in scenario S1), but prioritised first to 
individuals aged ≥30 years and people who inject drugs (PWID), 
who have increased hepatitis C prevalence, and then to the rest 
of the general population.
Scenario S3
Prioritised one-time screening (as in scenario S2), but with 
periodic RNA rescreening of cured individuals and those 
previously screened RNA-negative, and antibody rescreening of 
individuals previously screened antibody-negative. Rescreening 
starts from 2020 and occurs every 10 years for non-PWID and 
annually for PWID.
Scenario S4
Following these scenarios, we then determined what further 
improvements to the cascade of care are needed to reduce 
hepatitis C incidence by 80% by 2030. These improvements 
include prioritised one-time screening as in scenario S3, but 
with increased referral to care (90%), double the primary 
antibody screening rate (12·4% per year), rescreening every 
5 years for non-PWID, and re-engaging those who were lost to 
follow-up (every 5 years for non-PWID and yearly for PWID; not 
included previously).
Antibody screening and rescreening RNA rescreening of antibody-positive individuals Referral: proportion 
of those diagnosed 
with hepatitis C 
who were linked to 
treatment (all)
Primary antibody 
screening* (all)
Rescreening of SVR and 
previously screened 
uninfected*
Previously treated Proportion of those 
diagnosed with hepatitis C 
who were lost to follow-up 
then linked back to care
General 
population
PWID General 
population
PWID General 
population
PWID
Scenario S0 ·· ·· ·· ·· ·· ·· ·· ··
Scenario SQ 2·6−5·9% ·· ·· ·· ·· ·· ·· 35−70%
Scenario S1 6·2% (6·1−6·3) ·· ·· ·· ·· ·· ·· 80%
Scenario S2 6·2% (6·1−6·3) ·· ·· ·· ·· ·· ·· 80%
Scenario S3 6·2% (6·1−6·3) 10% 100% 10% 100% ·· ·· 80%
Scenario S4 12·4% (12·1−12·6) 20% 100% 20% 100% 20% 100% 90%
An annual primary screening rate of 6·2% (6·1–6·3) is equivalent to first-time antibody screening of 180 million (175−185) individuals, or 90% of the 2018 population, by 2030. 
Doubling this annual primary screening rate to 12·4% (12·1−12·6) is equivalent to first-time antibody screening of 280 million (265−290) individuals, or 140% of the 2018 
population, by 2030. General population refers to individuals who do not inject drugs. PWID=people who inject drugs. SVR=sustained virological response. *We assume that all 
people who tested antibody-positive, either from primary antibody screening (ψ₁) or antibody rescreening (ψ₂), are subsequently tested for hepatitis C virus RNA (ie, there is no 
loss to follow-up at this stage).
Table 2: Model parameters for each screening and treatment intervention scenario, 2018 onwards
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p 35). We also estimated the cost per cure for each 
strategy. Costs and outcomes were discounted at 3·5% 
per year. More details are given in the appendix 
(pp 16–17, 34–39).
Sensitivity analyses
We did sensitivity analyses to determine how the total 
costs of scenario S4 would vary for the following changes 
in cost assumptions: X1: assume lowest Pakistan direct-
acting antiviral drug costs ($18 vs $109 for 12 weeks); 
X2: assume lowest costs for diagnostic test kits 
($0·40 vs $2·15 for antibody test, $15 vs $24 for RNA 
confirmation); X3: include savings in health-care costs for 
managing patients with hepatitis C-related disease—cost 
data from Cambodia adjusted to the Pakistan context (pre-
cirrhosis: $15, compensated cirrhosis: $47, decompensated 
cirrhosis: $278, hepatocellular carcinoma: $339, compared 
to no health-care costs in the base case); X4: include costs 
for improving referral from 80% to 90% of diagnosed 
chronic infections and re-engaging people who have been 
lost to follow-up ($19 per patient referred or re-engaged, 
derived from assuming half a day of nurse time required 
to follow-up each patient); X5: include savings from 
implementing a simplified treatment pathway (reduced 
visits and laboratory investigations); X6: combine X1 to X5; 
and X7 and X8: no discount rate or double the discount 
rate for costs and outcomes (3·5% in base analyses). 
Further details are given in the appendix (p 35).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Without treatment from 2018 (S0), our model projects 
that prevalence of chronic hepatitis C will rise from 
3·7% (95% UI 3·4–4·0) in 2018 to 4·5% (4·0–5·1) in 
2030 (ie, 11·2 million [10·1–12·4] chronic infections in 
2030). Hepatitis C incidence will rise from 3·4 (95% UI 
3·0–3·9) per 1000 person-years in 2018 (660 000 
[580 000–750 000] incident HCV infections) to 4·1 
(3·5–4·8) per 1000 person-years in 2030 (950 000 
[820 000–1 100 000] incident HCV infections); the latter 
being an increase in incidence of 19·5% (12·5–27·1) 
relative to 2015 levels (figure 2; appendix p 40). If 
current levels of treatment are continued (SQ), 25·0% 
(95% UI 22·5–28·0) of chronic infections in 2018 
would be cured by 2030, chronic hepatitis C prevalence 
and incidence would remain stable, but hepatitis 
C-related mortality would increase by 32·3% 
(25·0–40·0) relative to 2015 (figure 2; appendix p 40). 
Figure 2 shows the effect of each inter vention scenario 
on hepatitis C mortality and incidence, with each 
cascade of care shown in figure 3.
For scenario S1, one-time screening of 90% of the 
general population in 2018–30 requires 13·8 million 
(95% UI 13·4–14·1) individuals or 6·2% (6·1–6·3) of 
the population being tested for hepatitis C antibody 
or RNA, or both, annually. On average, 350 000 
(95% UI 315 000–385 000) treatments are started 
annually and 56·4% (54·8–58·0) of chronic infections 
in 2018 are cured by 2030 (appendix p 40). Compared 
with 2015 levels, incidence decreases by 26·5% (95% UI 
22·5–30·7) by 2030 but mortality increases by 7·0% 
(1·1–13·5; figure 2). By 2030, both incidence and 
mortality are likely to decrease compared with baseline 
scenarios S0 and SQ.
Compared with scenario S1, scenario S2 (one-time 
screening with prioritisation for PWID and adults aged 
≥30 years) results in the annual treatments increasing to 
445 000 (95% UI 400 000–490 000) and 72·9% (71·4–74·3) 
of chronic infections in 2018 being cured by 2030 
(appendix p 40). Incidence decreases by 40·8% (95% UI 
36·4–45·4) and mortality by 14·8% (7·8–21·1) compared 
with scenario S0 for 2018–30 (figure 2).
For scenario S3, incorporating rescreening of pre-
viously treated individuals and individuals who 
previously tested antibody-negative increases the number 
of individuals screened by about 46·8%, compared with 
scenarios S1 and S2, to 20·2 million (95% UI 19·7–20·7) 
individuals annually. This increase results in 490 000 
(95% UI 445 000–545 000) individuals being treated each 
year and 80·5% (78·2–82·8%) of chronic infections in 
2018 being cured by 2030 (figure 3; appendix p 40). 
Incidence decreases by 50·8% (95% UI 46·1–55·0) and 
mortality by 17·9% (10·8–24·3%) compared with 
scenario S0 for 2018–30 (figure 2).
For scenario S4, incremental to scenario S3, doubling 
the primary screening rate (12·4% per year), improving 
treatment referral (90%), rescreening non-PWID every 
Figure 2: Relative change in incidence and mortality achieved by 2030 versus 2015, by intervention scenario
Data are the median of 1151 final model runs. Error bars are 95% uncertainty intervals. Scenario S0: no screening or 
treatment from 2018 onwards. Scenario SQ: maintaining status quo treatment of 150 000–160 000 annual 
treatments from 2018. Scenario S1: one-time random screening of 90% of the general population of Pakistan by 
2030, with 80% referral to care. Scenario S2: scenario S1 plus prioritised screening of people aged ≥30 years and 
PWID. Scenario S3: scenario S2 plus rescreening of cured and previously antibody-negative or RNA-negative 
individuals from 2020 (every 10 years for non-PWID and annually for PWID). Scenario S4: scenario S3 with 
incremental improvements to achieve elimination. PWID=people who inject drugs.
S0 SQ S1 S2 S3 S4
Intervention scenario
–100
–80
100
80
60
40
20
0
–20
–40
–60
Ch
an
ge
 in
 h
ep
at
iti
s C
 v
iru
s b
ur
de
n 
(%
)
Change in incidence achieved by 2030 (%)
Change in mortality achieved by 2030 (%)
WHO 80% incidence reduction target
WHO 65% mortality reduction target
Articles
www.thelancet.com/lancetgh   Vol 8   March 2020 e446
5 years (instead of every 10 years), and re-engaging 
individuals who have been lost to follow-up back into care 
(every 5 years), substantially increased the number of 
people screened (via antibody or RNA testing) annually to 
36·4 million (95% UI 35·1–37·8). Overall, 139·7% 
(95% UI 135·5–144·6) of the population in 2018 are 
screened by 2030 and 109·0% (107·0–111·4) of chronic 
infections in 2018 are cured, with 660 000 (595 000–735 000) 
being treated annually. Incidence decreases by 84·8% 
(95% UI 79·7–87·4) and mortality by 52·1% (43·0–59·3; 
figure 2), reaching a 65% reduction in mortality by 2035 
(appendix pp 23, 40). The doubling in primary screening 
rate and the increase in referral had the most benefit in 
terms of reducing incidence (appendix p 24).
For scenarios S1–S4, the model suggests that 
one person will be treated for every 33–57 screening tests 
done, with scenario S2 achieving the lowest number of 
tests per treatment (appendix pp 25, 41).
For scenarios S1–S3, the median estimated cost of 
the different intervention scenarios for 2018–30 was 
$3·4–5·1 billion (figure 4A), with the cost increasing for 
each successive scenario and 50–60% of costs being 
due to screening (appendix p 41). To reach the WHO 
elimination target for incidence (an 80% reduction), 
scenario S4 increases the total screening and treatment 
costs by two-thirds (vs scenario S3) to $8·1 billion 
(95% UI 7·7–8·5) for 2018–30. The cost per cure is 
$900–1200 for scenarios S1–S4 and is cheapest for 
scenario S2 (figure 4B).
Our sensitivity analyses showed that reducing the 
costs of either direct-acting antiviral regimens (X1) or 
diagnostic test kits (X2) to the lowest available price 
could each reduce total costs by 10% (vs the baseline of 
$8·1 billion) to about $7·2 billion separately, while 
including savings in health-care costs (X3) could reduce 
total costs by 13% to $7·0 billion; figure 5). The 
inclusion of costs for improving referral and re-
engaging patients who were lost to follow-up (X4) will 
probably have a minimal effect on total costs (<1% 
change). Notably, the implementation of a simplified 
screening and treatment pathway (X5) could have a 
considerable effect on costs, reducing the overall budget 
for eliminating hepatitis C by 16% to $6·7 billion, while 
combining the effects of X1–X5 (X6) could reduce costs 
by 52% (vs the baseline) to $3·9 billion by 2030. This 
saving results in a cost of $600 per cure, with the 
annual costs equating to about 9·0% of the current 
health expenditure in Pakistan (2017–18 fiscal year)14—
which is 0·11% of gross domestic product in 2017–18,23 
or about $1·50 per person per year for the population in 
2018. Changing the discount rate to either 0% (X7) or 
7% (X8) varies the total costs by roughly 20%. Further 
reductions in costs of test kits and direct-acting 
antivirals, possibly due to bulk purchasing, would 
only decrease costs marginally, with a 25% reduction 
in both only decreasing overall costs to $3·7 billion 
(appendix p 29).
Figure 3: Cascade of care for scenarios S1–S4
Data are the median of 1151 final model runs. Error bars are 95% uncertainty intervals. The height of each bar is the 
proportion of cases (absolute numbers given within each bar) that are diagnosed, referred, initiated treatment, and 
achieved a sustained virological response relative to the chronic HCV burden in 2018 in the first bar corresponding 
to 100% (shaded in grey). The full height of the chronic HCV bar shows the full burden of HCV infections in 
2018–30 for each scenario, which is the sum of the chronic HCV burden in 2018 with all new chronic infections that 
occur from 2018 until 2030 in that scenario. The arrows between each bar show the percentage of the previous 
step in the cascade of care that moves onto the following step. (A) Scenario S1: one-time random screening 
of 90% of the general population of Pakistan by 2030, with 80% referral to care. (B) Scenario S2: scenario S1 plus 
prioritised screening of people aged ≥30 years and PWID. (C) Scenario S3: scenario S2 plus rescreening of cured and 
previously antibody-negative or RNA-negative individuals from 2020 (every 10 years for non-PWID and annually 
for PWID). (D) Scenario S4: scenario S3 plus incremental improvements to achieve elimination. HCV=hepatitis C 
virus. PWID=people who inject drugs. SVR=sustained virological response. 
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Discussion
Our findings suggest that considerable screening of 
hepatitis C and effective referral to treatment is needed 
to achieve the WHO elimination target for hepatitis C 
incidence in Pakistan. Indeed, due to population growth 
and the expanding epidemic in Pakistan, our projections 
suggest that, to meet the target, 140% of the current 
Pakistan population (or 278 million people) will need to 
be screened for hepatitis C during 2018–30, 90% of 
diagnosed individuals will need to be linked to treatment, 
interventions will need to re-engage individuals who have 
been lost to follow-up, and regular rescreening will need 
to identify new reinfections. Although cheap treatments 
and diagnostics are available in Pakistan (the cheapest 
direct-acting antiviral is $18 per 12-week treatment 
course), our estimates suggest that at its cheapest, this 
screening and treatment strategy will cost US$3·9 billion 
over 13 years, with the yearly costs making up 9·0% of the 
annual health budget of Pakistan (2017–18 fiscal year).14 
This cost translates to about $600 per cured individual.
Irrespective of the approach chosen, substantial 
improvements in the cascade of care for hepatitis C are 
required in Pakistan. First, primary antibody screening 
rates need to be high to identify prevalent and incident 
infections. The yield of this screening can be improved 
through prioritising high prevalence subgroups or using 
other risk-based criteria for deciding whom to screen.8 
However, it is important that such risk-based screening 
algorithms are evaluated before being deployed to 
ensure that they capture most infections. Second, 
referral rates need to be high, as shown by Egypt’s 
national testing and treatment programme, which has 
treated 88% of all diagnosed patients.24 Development of 
improved diagnostics, such as point-of-care tests for 
active hepatitis C infection, could help with improving 
referral by simplifying the pathway from hepatitis C 
diagnosis to treatment,25,26 as achieved with HIV point-
of-care testing in LMICs.27 Simplifying the treatment 
pathway in other ways and using incentives or nurse 
facilitators to reduce loss to follow-up could also increase 
the number of individuals being referred to treatment.28,29 
Lastly, because of continued risk of exposure to 
hepatitis C infection in the community, repeat screening 
is needed to identify reinfections; such rescreening is 
likely to incur substantial additional costs unless it can 
be targeted to those with identified risk.
Crucially, this work emphasises the immense effort and 
financial burden of a national hepatitis C elimination 
initiative in Pakistan. Our analyses show that a screen-all 
approach will be needed, requiring improved access to 
screening for all patient subgroups, including marginalised 
subpopulations—such as PWID, men who have sex with 
men, and patients with end-stage liver disease.30
The main strength of our study is that, to our 
knowledge, it is the first to use detailed dynamic 
modelling to undertake a cost–impact analysis of what is 
needed to achieve the WHO hepatitis C elimination 
targets in a LMIC. In the Pakistan context, our cost 
estimates use local cost data based on real pathways of 
care to derive realistic cost projections for the actual 
implementation of screening and treatment in this 
setting. These budgetary estimates provide a basis to 
assess the economic feasibility of a large-scale hepatitis C 
screening and treatment programme for achieving 
hepatitis C elimination, which is crucial information for 
governments and other decision makers. The present 
modelling analyses have fed into discussions with the 
Government of Pakistan who, on World Hepatitis Day 
2019, announced a new Prime Minister’s Programme 
declaring the government’s commitment to combating 
hepatitis C.31
Our analysis has several limitations. First, we did not 
include the added costs of improving the infrastructure 
Figure 4: Estimated total screening and treatment costs (A) and median 
costs per cure (B) for each intervention scenario over 2018–30
Data are the median of 1151 final model runs. Error bars are 95% uncertainty 
intervals. Costs and outcomes are discounted at a standard rate of 3·5% per year. 
The proportion of total costs that are due to screening were 53% for S1, 47% for S2, 
54% for S3, and 59% for S4. (A) Scenario S1: one-time random screening of 90% of 
the general population of Pakistan by 2030, with 80% referral to care. 
(B) Scenario S2: scenario S1 plus prioritised screening of people aged ≥30 years and 
PWID. (C) Scenario S3: scenario S2 plus rescreening of cured and previously 
antibody-negative or RNA-negative individuals from 2020 (every 10 years for 
non-PWID and annually for PWID). (D) Scenario S4: scenario S3 plus incremental 
improvements to achieve elimination. PWID=people who inject drugs.
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in Pakistan to enable country-wide hepatitis C screening. 
Second, to estimate the cost savings related to prevented 
health-care provision for hepatitis C-associated mor-
bidities, we adapted costs from Cambodia (appendix 
p 35) because data for Pakistan were not available. These 
savings offset 13% of the screening and treatment costs, 
emphasising the importance of obtaining local data to 
validate these estimates. Third, except for injecting 
drug use, we did not include any other risk-based 
stratifications in the model, so it was not possible to 
properly evaluate risk-based screening or rescreening, 
which could be more efficient than the screening 
scenarios we modelled. Moreover, although the model 
probably captures the main characteristics of how 
injecting drug use con tributes to overall transmission of 
hepatitis C in Pakistan, added detail could be included 
on variations in the age that people start injecting drug 
use and their duration of injecting. Fourth, further 
modelling could also consider the effect and potential 
costs of scaling up prevention interventions, which 
preliminary projections (data not shown) suggest could 
dramatically reduce the screening and treatment 
required for achieving hepatitis C elimination, especially 
if the interventions are effective for the general 
population. However, evidence for the cost and 
effectiveness of suitable interventions for the general 
population do not exist, thus we did not include this 
scenario in our analyses. Fifth, we did not estimate the 
screening requirements and costs of achieving the WHO 
elimination target for mortality by 2030. In our analyses, 
even the most aggressive intervention (scenario S4) only 
reached the 65% mortality reduction target by 2035, 
possibly suggesting that the mortality target might 
not be feasible by 2030. Lastly, in Pakistan, health-
care decisions are made at the provincial, rather 
than national, level following the devolution of 
the national health programme in 2010.9 More detailed 
regional models are needed to determine geographical 
differences in the screening and treatment strategies 
needed in Pakistan’s highly variable epidemics.
We have previously examined the required treatment 
scale up needed to reach the WHO elimination targets in 
Pakistan.5 This analysis builds upon our previous work 
by determining the screening requirements and likely 
costs of achieving these targets.
Few studies have examined the effects and budgetary 
implications of hepatitis C screening and treatment 
interventions in LMICs. A test-and-treat demonstration 
project studied the impact and cost-effectiveness of 
hepatitis C micro-elimination in rural Egypt.32 An 
analysis for South Africa considered the budgetary 
requirements for scaling up hepatitis C screening and 
treatment,33 while analyses in eastern Europe and central 
Asia evaluated the cost-effectiveness of intervention 
packages for reducing hepatitis C transmission among 
PWID.34 However, only the Egypt study32 used real 
context-specific cost data and none of these analyses 
incorporated the cascade of care into their models, nor 
did they estimate the level of screening and treatment 
needed for hepatitis C elimination. Moreover, the two 
analyses32,33 considering hepatitis C epidemics in the 
general population did not account for population growth 
or the effect of inter ventions on ongoing hepatitis C 
transmission, both of which are key factors characterising 
the hepatitis C epidemic in Pakistan and other LMICs.
One other study35 considered the cost of achieving the 
hepatitis C elimination target for mortality in Pakistan. 
However, the projections were based on conservative 
assumptions for the number of incident hepatitis C 
infections (280 000 per year in 2018 instead of 660 000 in 
our model) occurring in Pakistan, likely due to the 
authors not modelling an increasing epidemic or 
Figure 5: Univariate sensitivity analysis on total costs for scenario S4
We did sensitivity analyses to determine how the total costs of scenario S4 would vary for the eight changes in cost assumptions. X1: assume lowest Pakistan direct-
acting antiviral drug costs ($18 vs $109 for 12 weeks); X2: assume lowest costs for diagnostic test kits ($0·40 vs $2·15 for antibody test, $15 vs $24 for RNA 
confirmation); X3: include savings in health-care costs for managing patients with hepatitis C-related disease; X4: include costs for improving referral 
from 80% to 90% of diagnosed chronic infections and reengaging people who have been lost to follow-up; X5: include savings from implementing a simplified 
treatment pathway (fewer visits and laboratory investigations); X6: combine X1 to X5; X7: no discounting of costs and outcomes (3·5% in base analyses); 
and X8: double the discount rate for costs and outcomes (3·5% in base analyses). Full details are in the appendix (pp 29, 34–35). LTFU=lost to follow-up. 
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growing popu lation; both of which are important 
characteristics of the Pakistan epidemic.5,36 Further, the 
health-care cost estimates in the previous study35 were 
adapted from US data and staff costs were not included 
in the costs of treatment, meaning the cost estimates 
might not reflect the real costs in a Pakistan context. Our 
study improves on this analysis through using primary 
cost data from Pakistan and detailed epidemiological 
data to calibrate the increasing hepatitis C epidemic in 
Pakistan.
Pakistan is a crucial target country for achieving global 
hepatitis C elimination because it harbours 10% of the 
global hepatitis C burden. Our findings suggest that 
considerable scale up of screening and treatment 
interventions will be required at substantial cost to 
achieve the WHO hepatitis C elimination targets in 
Pakistan. Estimated annual screening and treatment 
costs could translate to around 9·0% of the current 
health expenditure of Pakistan (2017–18 fiscal year), with 
this equating to 0·11% of gross domestic product in 
2017–18, or about $1·50 per person per year.14 The 
government of Pakistan has already made substantial 
progress in starting hepatitis C prevention and control 
programmes9 and, although political will exists,9,36 greater 
health sector investment is required to effectively tackle 
the growing hepatitis C burden in Pakistan. Although 
specific to Pakistan, the insights from this study are 
applicable to other resource-limited settings with a high 
prevalence of hepatitis C. Our analyses show that the 
substantial costs of achieving hepatitis C elimination can 
be reduced dramatically through improving accessibility 
to cheaper drugs and diagnostics tests and by developing 
simplified screening and treatment algorithms. These 
findings could inform how other countries can work 
towards scaling up hepatitis C screening and treatment. 
To achieve global hepatitis C elimination, it is of para-
mount importance that hepatitis C epidemics be tackled 
in settings such as Pakistan that have a high burden 
of hepatitis C; widespread intervention scale up and 
resource investment should not be delayed.
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